AR013184A1 - Aminas heterociclicas espiroazobiciclicas, composicion farmaceutica, uso de dichas aminas para preparar medicamentos y metodo de tratamiento o profilaxis - Google Patents

Aminas heterociclicas espiroazobiciclicas, composicion farmaceutica, uso de dichas aminas para preparar medicamentos y metodo de tratamiento o profilaxis

Info

Publication number
AR013184A1
AR013184A1 ARP980103280A ARP980103280A AR013184A1 AR 013184 A1 AR013184 A1 AR 013184A1 AR P980103280 A ARP980103280 A AR P980103280A AR P980103280 A ARP980103280 A AR P980103280A AR 013184 A1 AR013184 A1 AR 013184A1
Authority
AR
Argentina
Prior art keywords
4alkyl
amines
prophylaxis
treatment
spyrozobicyclic
Prior art date
Application number
ARP980103280A
Other languages
English (en)
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from SE9702746A external-priority patent/SE9702746D0/xx
Priority claimed from SE9800977A external-priority patent/SE9800977D0/xx
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of AR013184A1 publication Critical patent/AR013184A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

Aminas heterocíclicas espiroazobiciclicas de la formula (I) en la cual n es 0 o 1; m es O o 1: p es O o 1; X es oxígeno o azufre; Y es CH, N o NO; W esoxígeno, H2 o F2; A es N o C(R2), G es N o C(R3), D es N o C(R4), con la condicion de queno más de uno de A, G y D sea nitrogeno pero al menos uno deY, A, G y D sea nitrogeno o NO; R1 es hidrogeno o alquilo C1-4, R2, R3 y R4 son independientemente hidrogeno, halogeno, alquilo C1-4, alquenilo C2-4, alquiniloC2-4, arilo, heteroarilo, OH,alq uilo OC1-4, CO2R1,-CN, NO2, -NR5R6, -CF3, -OSO2CF3, o R2 y R3 o R3 Y R4, respectivamente pueden formar juntos otro anilloaromático o heteroaromático de seis miembros que comprate A y G, o G y D, respectivamente que contiene entre ceroy do s átomos de nitrogeno y estásustituido con uno o dos de los siguientes sustituyentes; independientemente hidrogeno, halogeno, alquilo C1-4, alquenilo C2-4, alquinilo C2-4, ariloheteroarilo, OH, alquilo Oc1-4, CO2R1, -CN -NO2, -NR5R6, -CF3, -OSO-CF 3; R5 y R6 representan independientemente hidrogeno, alquilo C1-4, C(O)R7, C(O)NHR8,C(O)OR9, SO2R10 o juntos pueden consistir en (CH2)jQ(CH2)k donde Q es O, S, NR11 o un enlace; j es 2 a 7; k es 0 o 2; R7, R8 R9, R10, R11sonindependientemente alquilo C1-4, arilo o heteroarilo, o un enantiomero del mismo, así como sales farmacéuticemente aceptables del mismo, procesos paraprepararlo, una composicion que lo contiene, y su uso en terapia y en la preparacionde medicamentos, y mé todos de tratamiento o profilaxis detrastornos psicoticos y trastornos de deterioro intelectual.
ARP980103280A 1997-07-18 1998-07-06 Aminas heterociclicas espiroazobiciclicas, composicion farmaceutica, uso de dichas aminas para preparar medicamentos y metodo de tratamiento o profilaxis AR013184A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9702746A SE9702746D0 (sv) 1997-07-18 1997-07-18 New compounds
SE9800977A SE9800977D0 (sv) 1998-03-24 1998-03-24 New compounds

Publications (1)

Publication Number Publication Date
AR013184A1 true AR013184A1 (es) 2000-12-13

Family

ID=26663041

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP980103280A AR013184A1 (es) 1997-07-18 1998-07-06 Aminas heterociclicas espiroazobiciclicas, composicion farmaceutica, uso de dichas aminas para preparar medicamentos y metodo de tratamiento o profilaxis
ARP080103670A AR068013A2 (es) 1997-07-18 2008-08-22 Compuestos uso de dicho compuesto para preparar medicamentos y composicion farmaceutica

Family Applications After (1)

Application Number Title Priority Date Filing Date
ARP080103670A AR068013A2 (es) 1997-07-18 2008-08-22 Compuestos uso de dicho compuesto para preparar medicamentos y composicion farmaceutica

Country Status (31)

Country Link
US (6) US6110914A (es)
EP (2) EP0996622B1 (es)
JP (1) JP2001510194A (es)
KR (1) KR100560036B1 (es)
CN (1) CN1117755C (es)
AR (2) AR013184A1 (es)
AT (2) ATE283859T1 (es)
AU (1) AU739022B2 (es)
BR (1) BR9810924A (es)
CA (1) CA2296031C (es)
DE (2) DE69808631T2 (es)
DK (1) DK0996622T3 (es)
EE (1) EE04399B1 (es)
ES (2) ES2231599T3 (es)
HK (3) HK1025322A1 (es)
HU (1) HUP0003844A3 (es)
ID (1) ID25548A (es)
IL (2) IL134086A0 (es)
IS (2) IS2027B (es)
MY (1) MY116761A (es)
NO (1) NO325324B1 (es)
NZ (1) NZ502298A (es)
PL (1) PL193065B1 (es)
PT (1) PT996622E (es)
RU (1) RU2202553C2 (es)
SA (1) SA98190668B1 (es)
SI (1) SI0996622T1 (es)
SK (1) SK283484B6 (es)
TR (1) TR200000129T2 (es)
TW (1) TW515799B (es)
WO (1) WO1999003859A1 (es)

Families Citing this family (110)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0984970B1 (en) 1997-05-30 2003-11-19 Neurosearch A/S Spiro-quinuclidine derivatives, their preparation and use
US7214686B2 (en) 1997-06-30 2007-05-08 Targacept, Inc. Pharmaceutical compositions and methods for effecting dopamine release
AR013184A1 (es) * 1997-07-18 2000-12-13 Astrazeneca Ab Aminas heterociclicas espiroazobiciclicas, composicion farmaceutica, uso de dichas aminas para preparar medicamentos y metodo de tratamiento o profilaxis
US6277870B1 (en) 1998-05-04 2001-08-21 Astra Ab Use
SE9900100D0 (sv) * 1999-01-15 1999-01-15 Astra Ab New compounds
FR2790474B1 (fr) * 1999-03-05 2001-04-06 Synthelabo Derives de pyridopyranoazepines, leur preparation et leur application en therapeutique
US8914114B2 (en) 2000-05-23 2014-12-16 The Feinstein Institute For Medical Research Inhibition of inflammatory cytokine production by cholinergic agonists and vagus nerve stimulation
TWI298068B (en) * 2000-06-21 2008-06-21 Dainippon Sumitomo Pharma Co Pharmaceutical composition for schizophrenia
US6569865B2 (en) 2001-06-01 2003-05-27 Astrazeneca Ab Spiro 1-azabicyclo[2.2.2]octane-3,2′(3′h)-furo[2,3-b]pyridine
DE60218032T2 (de) * 2001-06-01 2007-08-16 Astrazeneca Ab Neuer, für die therapie geeigneter ligand für nikotinische acetylcholinrezeptoren
WO2003032897A2 (en) * 2001-10-16 2003-04-24 Astrazeneca Ab Azabicyclic compounds for the treatment of fibromyalgia syndrome
US7067261B2 (en) * 2001-12-14 2006-06-27 Targacept, Inc. Methods and compositions for treatment of central nervous system disorders
DE10164139A1 (de) 2001-12-27 2003-07-10 Bayer Ag 2-Heteroarylcarbonsäureamide
US20030162770A1 (en) 2002-02-22 2003-08-28 Davis Bonnie M. Use of modulators of nicotinic receptors for treatment of cognitive dysfunction
WO2003087102A1 (en) * 2002-04-18 2003-10-23 Astrazeneca Ab Furyl compounds
AU2003224546B2 (en) * 2002-04-18 2008-11-06 Astrazeneca Ab Heterocyclic compounds
CN1325499C (zh) * 2002-04-18 2007-07-11 阿斯特拉曾尼卡有限公司 噻吩基化合物
JP4667867B2 (ja) 2002-08-02 2011-04-13 メルク・シャープ・エンド・ドーム・コーポレイション 置換フロ［２，３−ｂ］ピリジン誘導体
SE0202598D0 (sv) * 2002-09-02 2002-09-02 Astrazeneca Ab Alpha-7 Nicotinic receptor agonists and statins in combination
GB0220581D0 (en) 2002-09-04 2002-10-09 Novartis Ag Organic Compound
US7238715B2 (en) * 2002-12-06 2007-07-03 The Feinstein Institute For Medical Research Treatment of pancreatitis using alpha 7 receptor-binding cholinergic agonists
AU2003298939B2 (en) 2002-12-06 2007-03-15 The Feinstein Institute For Medical Research Inhibition of inflamation using alpha 7 receptor-binding cholinergic agonists
WO2004063201A1 (ja) * 2003-01-08 2004-07-29 Mitsubishi Pharma Corporation 統合失調症治療剤
US20050129610A1 (en) * 2003-06-24 2005-06-16 Johns Hopkins University Imaging agents and methods of imaging alpha7-nicotinic cholinergic receptor
WO2005030778A1 (en) 2003-09-25 2005-04-07 Astrazeneca Ab Ligands
ATE451368T1 (de) 2003-10-15 2009-12-15 Targacept Inc Azabicyclische verbindungen zur linderung von schmerzen und zur behandlung von erkrankungen des zentralen nervensystems
EP1678183A1 (en) * 2003-10-21 2006-07-12 AstraZeneca AB Spirofuropyridine aryl derivatives
US20070191815A1 (en) 2004-09-13 2007-08-16 Chrono Therapeutics, Inc. Biosynchronous transdermal drug delivery
US10912712B2 (en) 2004-03-25 2021-02-09 The Feinstein Institutes For Medical Research Treatment of bleeding by non-invasive stimulation
JP2007530586A (ja) 2004-03-25 2007-11-01 ザ ファインスタイン インスティテュート フォー メディカル リサーチ 神経性止血法
AR049401A1 (es) 2004-06-18 2006-07-26 Novartis Ag Aza-biciclononanos
GB0415746D0 (en) 2004-07-14 2004-08-18 Novartis Ag Organic compounds
JP2008525102A (ja) 2004-12-27 2008-07-17 ノース ショア−ロング アイランド ジューウィッシュ リサーチ インスティテュート 電気的な迷走神経刺激による炎症性障害の処置
US11207518B2 (en) 2004-12-27 2021-12-28 The Feinstein Institutes For Medical Research Treating inflammatory disorders by stimulation of the cholinergic anti-inflammatory pathway
NZ565628A (en) 2005-08-22 2011-03-31 Targacept Inc Heteroaryl-substituted diazatricycloalkanes, methods for its preparation and use thereof
GB0521508D0 (en) 2005-10-21 2005-11-30 Novartis Ag Organic compounds
US8316104B2 (en) 2005-11-15 2012-11-20 California Institute Of Technology Method and apparatus for collaborative system
GB0525673D0 (en) 2005-12-16 2006-01-25 Novartis Ag Organic compounds
GB0525672D0 (en) 2005-12-16 2006-01-25 Novartis Ag Organic compounds
TW200813067A (en) * 2006-05-17 2008-03-16 Astrazeneca Ab Nicotinic acetylcholine receptor ligands
US7999107B2 (en) 2007-01-31 2011-08-16 Merck Sharp & Dohme Corp. Substituted pyrano[2,3-B]pyridine derivatives as cannabinoid-1 receptor modulators
US20080242688A1 (en) * 2007-03-19 2008-10-02 Astrazeneca Ab Method 741
AU2008232453B8 (en) 2007-04-02 2011-07-21 Parkinson's Institute Methods and compositions for reduction of side effects of therapeutic treatments
WO2009017454A1 (en) * 2007-07-30 2009-02-05 Astrazeneca Ab New therapeutic combination of a gsk3 inhibitor and an a7-nicotinic agonist 960
SA08290475B1 (ar) 2007-08-02 2013-06-22 Targacept Inc (2s، 3r)-n-(2-((3-بيردينيل)ميثيل)-1-آزا بيسيكلو[2، 2، 2]أوكت-3-يل)بنزو فيوران-2-كربوكساميد، وصور أملاحه الجديدة وطرق استخدامه
US8391970B2 (en) 2007-08-27 2013-03-05 The Feinstein Institute For Medical Research Devices and methods for inhibiting granulocyte activation by neural stimulation
DK2217597T3 (da) 2007-10-01 2011-06-20 Comentis Inc Quinuclidin-4-ylmethyl-1h-indol-3-carboxylatderivater som alpha-7-nicotin-acetylcholin-receptor-ligander til behandling af Alzheimers sygdom
DK2254598T3 (da) 2008-02-13 2013-07-29 Targacept Inc Kombination af alfa 7-nikotinagonister og antipsykotika
US9662490B2 (en) 2008-03-31 2017-05-30 The Feinstein Institute For Medical Research Methods and systems for reducing inflammation by neuromodulation and administration of an anti-inflammatory drug
WO2009146030A1 (en) 2008-03-31 2009-12-03 The Feinstein Institute For Medical Research Methods and systems for reducing inflammation by neuromodulation of t-cell activity
EA201001889A1 (ru) 2008-06-20 2011-08-30 Астразенека Аб Производные дибензотиазепина и их применение
WO2010059617A2 (en) 2008-11-18 2010-05-27 Setpoint Medical Corporation Devices and methods for optimizing electrode placement for anti-inflamatory stimulation
TW201031664A (en) 2009-01-26 2010-09-01 Targacept Inc Preparation and therapeutic applications of (2S,3R)-N-2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)-3,5-difluorobenzamide
US8996116B2 (en) 2009-10-30 2015-03-31 Setpoint Medical Corporation Modulation of the cholinergic anti-inflammatory pathway to treat pain or addiction
US8886339B2 (en) 2009-06-09 2014-11-11 Setpoint Medical Corporation Nerve cuff with pocket for leadless stimulator
US9211410B2 (en) 2009-05-01 2015-12-15 Setpoint Medical Corporation Extremely low duty-cycle activation of the cholinergic anti-inflammatory pathway to treat chronic inflammation
WO2011051350A1 (en) 2009-10-27 2011-05-05 Ucb Pharma S.A. Function modifying nav 1.7 antibodies
GB0922434D0 (en) 2009-12-22 2010-02-03 Ucb Pharma Sa antibodies and fragments thereof
US9234037B2 (en) 2009-10-27 2016-01-12 Ucb Biopharma Sprl Method to generate antibodies to ion channels
GB0922435D0 (en) 2009-12-22 2010-02-03 Ucb Pharma Sa Method
US11051744B2 (en) 2009-11-17 2021-07-06 Setpoint Medical Corporation Closed-loop vagus nerve stimulation
US9833621B2 (en) 2011-09-23 2017-12-05 Setpoint Medical Corporation Modulation of sirtuins by vagus nerve stimulation
AU2010336337B2 (en) 2009-12-23 2016-02-04 Setpoint Medical Corporation Neural stimulation devices and systems for treatment of chronic inflammation
WO2011116282A2 (en) 2010-03-19 2011-09-22 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Nicotinic acetylcholine receptor agonists
WO2011146511A1 (en) 2010-05-17 2011-11-24 Envivo Pharmaceuticals, Inc. A crystalline form of (r)-7-chloro-n-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide hydrochloride monohydrate
EP2707094B1 (en) 2011-05-09 2016-02-03 Setpoint Medical Corporation Single-pulse activation of the cholinergic anti-inflammatory pathway to treat chronic inflammation
RU2455306C1 (ru) * 2011-05-19 2012-07-10 Государственное образовательное учреждение высшего профессионального образования "Российский университет дружбы народов" (РУДН) СПОСОБ ПОЛУЧЕНИЯ ПРОИЗВОДНЫХ 3',4',5,6-ТЕТРАГИДРО-1Н-СПИРО[ПИРИДИН-4,5'-ТИЕНО[2,3-d]ПИРИМИДИНОВ]
JPWO2013002365A1 (ja) 2011-06-30 2015-02-23 東レ株式会社 止痒剤
GB201111704D0 (en) 2011-07-07 2011-08-24 Takeda Pharmaceutical Novel compounds
GB201111705D0 (en) 2011-07-07 2011-08-24 Takeda Pharmaceutical Compounds and their use
JO3115B1 (ar) 2011-08-22 2017-09-20 Takeda Pharmaceuticals Co مركبات بيريدازينون واستخدامها كمثبطات daao
US9572983B2 (en) 2012-03-26 2017-02-21 Setpoint Medical Corporation Devices and methods for modulation of bone erosion
AU2013259871A1 (en) 2012-05-08 2014-11-20 Forum Pharmaceuticals Inc. Methods of maintaining, treating or improving cognitive function
GB201209587D0 (en) 2012-05-30 2012-07-11 Takeda Pharmaceutical Therapeutic compounds
WO2014122474A1 (en) 2013-02-07 2014-08-14 Takeda Pharmaceutical Company Limited Piperidin-1 -yl and azepin-1 -yl carboxylates as muscarinic m4 receptor agonists
US8893339B2 (en) 2013-03-14 2014-11-25 Select Comfort Corporation System and method for adjusting settings of a bed with a remote control
EP3010900B1 (en) 2013-06-21 2018-01-03 Takeda Pharmaceutical Company Limited 1-sulfonyl piperidine derivatives as modulators of prokineticin receptors
GB201314286D0 (en) 2013-08-08 2013-09-25 Takeda Pharmaceutical Therapeutic Compounds
GB201318222D0 (en) 2013-10-15 2013-11-27 Takeda Pharmaceutical Novel compounds
GB201320905D0 (en) 2013-11-27 2014-01-08 Takeda Pharmaceutical Therapeutic compounds
US9067998B1 (en) 2014-07-15 2015-06-30 Kymab Limited Targeting PD-1 variants for treatment of cancer
US9914769B2 (en) 2014-07-15 2018-03-13 Kymab Limited Precision medicine for cholesterol treatment
US9045545B1 (en) 2014-07-15 2015-06-02 Kymab Limited Precision medicine by targeting PD-L1 variants for treatment of cancer
US8986694B1 (en) 2014-07-15 2015-03-24 Kymab Limited Targeting human nav1.7 variants for treatment of pain
US8992927B1 (en) 2014-07-15 2015-03-31 Kymab Limited Targeting human NAV1.7 variants for treatment of pain
TW201613864A (en) 2014-02-20 2016-04-16 Takeda Pharmaceutical Novel compounds
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
EP3166940A4 (en) 2014-07-11 2018-04-25 Alpharmagen, LLC Quinuclidine compounds for modulating alpha7 -nicotinic acetylcholine receptor activity
US9139648B1 (en) 2014-07-15 2015-09-22 Kymab Limited Precision medicine by targeting human NAV1.9 variants for treatment of pain
US11311725B2 (en) 2014-10-24 2022-04-26 Setpoint Medical Corporation Systems and methods for stimulating and/or monitoring loci in the brain to treat inflammation and to enhance vagus nerve stimulation
WO2016123406A1 (en) 2015-01-28 2016-08-04 Chrono Therapeutics Inc. Drug delivery methods and systems
WO2016126807A1 (en) 2015-02-03 2016-08-11 Setpoint Medical Corporation Apparatus and method for reminding, prompting, or alerting a patient with an implanted stimulator
US9724340B2 (en) 2015-07-31 2017-08-08 Attenua, Inc. Antitussive compositions and methods
US10596367B2 (en) 2016-01-13 2020-03-24 Setpoint Medical Corporation Systems and methods for establishing a nerve block
US10695569B2 (en) 2016-01-20 2020-06-30 Setpoint Medical Corporation Control of vagal stimulation
US11471681B2 (en) 2016-01-20 2022-10-18 Setpoint Medical Corporation Batteryless implantable microstimulators
EP3405255A4 (en) 2016-01-20 2019-10-16 Setpoint Medical Corporation IMPLANTABLE MICROSTIMULATORS AND INDUCTION RECHARGE SYSTEMS
US10583304B2 (en) 2016-01-25 2020-03-10 Setpoint Medical Corporation Implantable neurostimulator having power control and thermal regulation and methods of use
GB201616839D0 (en) 2016-10-04 2016-11-16 Takeda Pharmaceutical Company Limited Therapeutic compounds
EP3534947A1 (en) 2016-11-03 2019-09-11 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses & methods
GB201619514D0 (en) 2016-11-18 2017-01-04 Takeda Pharmaceuticals Co Novel compounds
AU2018205529B2 (en) 2017-01-06 2023-08-10 Morningside Venture Investments Limited Transdermal drug delivery devices and methods
US11173307B2 (en) 2017-08-14 2021-11-16 Setpoint Medical Corporation Vagus nerve stimulation pre-screening test
US11660443B2 (en) 2018-04-20 2023-05-30 The Feinstein Institutes For Medical Research Methods and apparatuses for reducing bleeding via electrical trigeminal nerve stimulation
JP7420797B2 (ja) 2018-05-29 2024-01-23 モーニングサイド ベンチャー インベストメンツ リミテッド 薬剤送達の方法及びシステム
WO2020064655A1 (en) 2018-09-24 2020-04-02 Astrazeneca Ab Azd0328 dosage regime for treating cognitive impairment
US11260229B2 (en) 2018-09-25 2022-03-01 The Feinstein Institutes For Medical Research Methods and apparatuses for reducing bleeding via coordinated trigeminal and vagal nerve stimulation
JP2021138648A (ja) 2020-03-04 2021-09-16 武田薬品工業株式会社 経口固形製剤
JP2023526080A (ja) 2020-05-21 2023-06-20 ザ・フェインステイン・インスティチュート・フォー・メディカル・リサーチ 迷走神経刺激のためのシステムおよび方法
CN115340736B (zh) * 2022-05-20 2023-09-29 扬州实嘉电缆材料有限公司 一种氮磷阻燃剂改性聚氯乙烯防火电缆料

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3681363A (en) * 1970-08-20 1972-08-01 Univ Temple Spiro(imidazolidine-4,3{40 -quinuclidine)-2,5-diones
ATE192157T1 (de) * 1994-08-24 2000-05-15 Astra Ab Therapeutisch verwendbare spiro-azabicyclische verbindungen
US5468875A (en) * 1994-12-22 1995-11-21 American Home Products Corporation 1-azabicycloheptane derivatives
ES2156998T3 (es) * 1995-07-28 2001-08-01 Abbott Lab Compuestos de furopiridina, tienopiridina, pirrolopiridina y de pirimidina, piridazina y triazina relacionados utiles para controlar la transmision sinaptica quimica.
AR013184A1 (es) * 1997-07-18 2000-12-13 Astrazeneca Ab Aminas heterociclicas espiroazobiciclicas, composicion farmaceutica, uso de dichas aminas para preparar medicamentos y metodo de tratamiento o profilaxis

Also Published As

Publication number Publication date
DK0996622T3 (da) 2002-12-30
DE69808631T2 (de) 2003-06-12
SA98190668B1 (ar) 2006-09-25
ATE283859T1 (de) 2004-12-15
PL193065B1 (pl) 2007-01-31
US6110914A (en) 2000-08-29
PL338259A1 (en) 2000-10-09
TW515799B (en) 2003-01-01
HK1025322A1 (en) 2000-11-10
ES2185185T3 (es) 2003-04-16
US20020187994A1 (en) 2002-12-12
IS5338A (is) 2000-01-13
TR200000129T2 (tr) 2000-07-21
IS2434B (is) 2008-10-15
US20050004099A1 (en) 2005-01-06
CA2296031A1 (en) 1999-01-28
NO20000226L (no) 2000-03-14
IL134086A (en) 2007-08-19
BR9810924A (pt) 2000-08-15
MY116761A (en) 2004-03-31
US20030166935A1 (en) 2003-09-04
US6703502B2 (en) 2004-03-09
US6706878B2 (en) 2004-03-16
KR20010021961A (es) 2001-03-15
IS2027B (is) 2005-08-15
EE04399B1 (et) 2004-12-15
DE69827977D1 (de) 2005-01-05
AU739022B2 (en) 2001-10-04
CA2296031C (en) 2008-01-08
HK1046274A1 (en) 2003-01-03
ATE225792T1 (de) 2002-10-15
EP1213291B1 (en) 2004-12-01
NO20000226D0 (no) 2000-01-17
IL134086A0 (en) 2001-04-30
KR100560036B1 (ko) 2006-03-13
NO325324B1 (no) 2008-03-31
HK1046274B (zh) 2005-05-20
IS7747A (is) 2005-03-16
EP1213291A1 (en) 2002-06-12
HUP0003844A3 (en) 2002-11-28
SK183599A3 (en) 2000-08-14
US20080153864A1 (en) 2008-06-26
SI0996622T1 (en) 2003-04-30
US6369224B1 (en) 2002-04-09
EE200000031A (et) 2000-10-16
AU8367998A (en) 1999-02-10
SK283484B6 (sk) 2003-08-05
ES2231599T3 (es) 2005-05-16
DE69808631D1 (de) 2002-11-14
CN1270592A (zh) 2000-10-18
RU2202553C2 (ru) 2003-04-20
AR068013A2 (es) 2009-10-28
US7507744B2 (en) 2009-03-24
NZ502298A (en) 2002-02-01
CN1117755C (zh) 2003-08-13
HUP0003844A2 (hu) 2001-07-30
WO1999003859A1 (en) 1999-01-28
JP2001510194A (ja) 2001-07-31
ID25548A (id) 2000-10-12
DE69827977T2 (de) 2005-12-08
HK1031382A1 (en) 2001-06-15
EP0996622B1 (en) 2002-10-09
PT996622E (pt) 2003-01-31
EP0996622A1 (en) 2000-05-03

Similar Documents

Publication Publication Date Title
AR013184A1 (es) Aminas heterociclicas espiroazobiciclicas, composicion farmaceutica, uso de dichas aminas para preparar medicamentos y metodo de tratamiento o profilaxis
BR0108456A (pt) Composto, uso de um composto, métodos de tratamento ou de profilaxia de distúrbios psicóticos ou distúrbios de deterioração intelectual e de doenças humanas, e ,processo para preparação de um composto
AR006720A1 (es) Un compuesto derivado de azahexano heterociclico, su uso para la preparacion de una composicion farmaceutica, procedimiento para prepararlo y una composicion farmaceutica que lo comprende
SV2003000876A (es) Quinazolinas como inhibidores de mmp-13
AR068413A2 (es) Derivados 8-amino, metodos de preparacion, composiciones farmaceuticas y su uso en terapia
AR007828A1 (es) Compuestos derivados de piridilpirrol, procedimiento de preparacion y composiciones farmaceuticas conteniendo los mismos
ES2058630T3 (es) Derivados de 2-(1-piperazinil)-4-fenilcicloalcanopiridinas, procedimientos de preparacion y composiciones farmaceuticas que los contienen.
JO2353B1 (en) New derivatives of mixed-ring fluoroglycosides and drugs containing these compounds and their use
ES2127919T3 (es) 4-amino-piridinas, procedimiento para su preparacion, asi como medicamentos que contienen estos compuestos.
SE0202463D0 (sv) Novel compounds
MX9200344A (es) Derivados de benzamida, proceso para su preparacion y composicion farmaceutica que los contiene.
TW200716528A (en) Cyclopropanecarboxamide derivatives
AP1687A (en) Therapeutic biaryl derivatives.
PE20080688A1 (es) Derivados de n-(amino-heteroaril)-1h-indol-2-carboxamidas como antagonistas de trpv1 y su preparacion
MX9305379A (es) Nuevos derivados de aminoacidos, procedimiento para su preparacion y preparado farmaceutico que los contiene.
TR199801594A2 (xx) CCR-3 resept�r antagonistleri.
SE0202133D0 (sv) Novel compounds
UY29312A1 (es) Piperazin-1-carboxamidas n,4,sustituidas y sus derivados, composiciones que los contienen, procedimientos de preparación y aplicaciones
CO5590895A2 (es) Derivados de sulfonamidas, su preparacion y su aplicacion como medicamentos
AR037907A1 (es) Derivados de azaindolilalquilamina como ligandos de 5-hidroxitriptamina-6
TW200505441A (en) Non-nucleoside reverse transcriptase inhibitorsⅠ
BR0015195A (pt) Composto, composição farmacêutica, uso de um composto, e, métodos para o tratamento de uma condição associada com a transmissão reduzida de nicotina para o tratamento ou profilaxia de distúrbios psicóticos ou distúrbios de deterioração intelectual e para o tratamento ou profilaxia de doenças ou condições humanas
ATE416157T1 (de) Inhibitoren von integrin alpha-v-beta-6
DK0556332T3 (da) Substituerede tetrahydropyridiner og hydroxypiperidiner som midler til behandling af centralnervesystemet
AR007108A1 (es) Agentes antitumorales y antivirales alquilantes, procedimiento para su preparacion, utilizacion de los mismos para la fabricacion de un medicamento y composicion farmaceutica que contiene a dichos agentes.

Legal Events

Date Code Title Description
FB Suspension of granting procedure